COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive registry-based cohort study of over 800,000 individuals
Vaccine,
Journal Year:
2024,
Volume and Issue:
42(15), P. 3420 - 3428
Published: April 18, 2024
Factors
related
with
COVID-19
vaccine
uptake
in
children
and
adolescents
Norway
remain
unclear,
despite
this
being
useful
knowledge
for
future
pandemic
preparedness.
This
study
aimed
to
comprehensively
examine
individual
familial
factors
associated
Norway.
We
utilized
nationwide
registry-data
from
various
health
registries
Statistics
Norway,
encompassing
all
living
during
the
pandemic,
until
31-Dec-2022.
Vaccine
is
defined
as
receiving
at
least
one
dose
of
vaccine.
employed
a
forward
stepwise
logistic
regression
model
random
forest
machine-learning
algorithm
explore
relationship
between
socio-cultural,
demographic,
health-related
factors.
included
423,548
5–11-year-olds,
269,830
12–15-year-olds,
120,854
16–17-year-olds.
these
three
groups
was
respectively
2.6
%,
73.3
87.3
%.
varied
by
age
group.
In
youngest
children,
immigrant
background
(Odds-ratio
(OR)
=
1.58,
95
%
confidence
interval
(CI)
(1.14–2.19)),
born
extremely
preterm
(OR
2.38,
CI
(1.60–3.54)),
having
risk
severe
5.40,
(4.69–6.23)
maternal
vaccination
6.34,
(5.35–7.53))
were
positively
uptake.
The
latter
two
also
strongly,
while
previous
SARS-CoV-2
infection
negatively
0.12,
(0.11–0.14).
Similar
findings
observed
differed
markedly
group,
major
socio-demographics
parental
status,
prior
infection,
but
premature
moderate
or
high
COVID-19.
Language: Английский
The effect of COVID-19 vaccination on symptomatic infection and related symptoms among preterm-born children aged 3–7 years in China
Dan Wang,
No information about this author
Jing Ning,
No information about this author
Jingke Cao
No information about this author
et al.
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: Oct. 25, 2024
Vaccination
plays
a
crucial
role
in
preventing
and
controlling
SARS-CoV-2
infections
as
well
their
associated
adverse
outcomes.
But
there
is
notable
lack
of
research
on
the
effectiveness
COVID-19
vaccination
children,
particularly
those
young
preterm-born
who
are
more
vulnerable
to
severe
outcomes
from
infection.
We
aimed
determine
effect
with
inactivated
vaccines
BBIBP-CorV
CoronaVac
symptomatic
infection
related
symptoms
children
aged
3-7
years
after
relaxation
prevention
control
measures
December
2022
China.
performed
retrospective
cohort
study
involving
242
data
were
collected
March
2023.
Logistic
regression
models
modified
Poisson
combined
entropy
balancing
used
explore
associations
against
COVID-19,
specific
symptoms,
persistent
one
month
recovery
COVID-19.
Of
recruited
156
(64.5%)
vaccinated
CoronaVac.
After
balancing,
covariates
balanced
between
unvaccinated
groups,
standardized
mean
difference
<
0.001.
said
lowered
risk
developing
(risk
ratio
[RR]
=
0.783;
95%
confidence
interval
[CI]:
(0.711,
0.861).
Likewise,
was
decline
pneumonia
(odds
[OR]
0.318;
CI
0.110,
0.913),
fever
(RR
0.710;
0.635,
0.794),
high
0.542;
0.297,
0.988),
sore
throat
(OR
0.304;
0.139,
0.664),
0.425;
0.182,
0.993).
Immunization
provides
protection
for
years.
Language: Английский